MarketVIEW: Clostridium difficile vaccines - KXNet.com - Bismarck/Minot/Williston/Dickinson-KXNEWS,ND

MarketVIEW: Clostridium difficile vaccines

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer



 

 

 

LONDON, July 7, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

MarketVIEW: Clostridium difficile vaccines



http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_clostridium_difficile_vaccines.html

Clostridium difficile (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDI). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever, tachycardia and psuedomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy. Although CDAD can be managed usually by stopping antibiotic therapy or the use of metronidazole and vancomycin treatment, patient mortality can still reach 6-30%. In some patients with toxic megacolon who require surgical intervention or colectomy, mortality can reach even higher rates of 35-50%.


This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of C.DIFF vaccines to 2030 in the major Western markets. All potential vaccine indications are modelled: with a focus on key target populations as defined by the enrolment criteria of the Sanofi phase 3 CDIFFENSE trial. Also included is an in-depth epidemiology forecast to 2030 including number of CDI cases per country drawing upon latest surveillance data (pan-European survey). A discussion of the potential cost effectiveness implications of the vaccine is included along with an up-to-date review of competitor programs and preclinical activity.


THIS PRODUCT IS AN EXECUTIVE PRESENTATION + 1 MODEL

Contents – Executive presentation (MS PowerPoint based)

Authors note
Executive summary
Model forecast comparisons: January 2014 v March 2013
Model forecast comparisons: January 2014 v March 2013 (table)
C.diff vaccines: key model outputs
C.diff vaccines: global value ($m), 2015-30
C.diff vaccines: global volume (doses), 2015-30
C.diff vaccines: global value, base scenario, 2015-30
C.diff vaccines: global value, elective admissions, 2015-30
C.diff vaccines: global value, LTCFs, 2015-30
Comments on latest C.diff epidemiology
Epidemiology forecast: incidence per country 2000-2030
C.diff vaccines: modelling commercial potential
C.diff vaccine opportunity: target product profile (TPP)
The role of a C.diff vaccine
Key model assumptions: overview
Vaccine target populations: overview
Vaccine target populations: Venn diagram
Vaccine target populations: Market sizing US, 2025
Pricing
Overview of modelling strategy: elective admissions
Target populations: US and England elective procedures
Target populations: Long-term care facilities
Target populations: "at risk" 65yrs+
Coverage rates (at least one dose, at least three doses)
Competitor landscape: overview
C.diff vaccines: research and development pipeline
Sanofi Pasteur: toxoid vaccine
Pfizer vaccines
Valneva
Preclinical programs
Epidemiology: situation overview
Acute care hospitals: US
Acute care hospitals: England
Acute care hospitals: Germany
Acute care hospitals: pan-European
Bibliography
Disclaimer
About VacZine Analytics

 


PAGES: ~65 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based)

Title sheet.
Charts-by target population.
Charts-by vaccine.
Vol Val by country
Vol Val Sanofi
Vol Val by 2nd entrant
Elective admissions 50 yrs +
USA
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Universal vaccination 65 yrs +
USA
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
At risk 65 yrs +
USA
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Long-term-care facilities (LTCF)
USA
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Existing CDI
USA
Canada
UK
France
Germany
Italy
Spain
Other EU
Australia
Sources
Global price summary
Population database.
Hospital database.
Hospital procedures (US)
Hospital procedures (England)
CDI cases (all ages)
US CDI epidemiology
UK CDI epidemiology
UK CDI by specialty
Germany CDI epidemiology
EU source data.

Worksheets = ~75



Read the full report:
MarketVIEW: Clostridium difficile vaccines

http://www.reportbuyer.com/pharma_healthcare/therapeutic/marketview_clostridium_difficile_vaccines.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow
General information or questions:
kxinfo@kxnet.com

News:
Bismarck:
Phone: 701-223-9197
News Fax: 701-223-1985

News:
Minot:
Phone: 701-852-2104
News Fax: 701-838-1050
All content © Copyright 2000 - 2014 WorldNow and KXNET. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.